The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Identification and Characterization of Compounds that Regulate the Activity of the LRRK2 System
Study Rationale: Genetic mutations that lead to the activation of the enzyme LRRK2 are a major cause of inherited Parkinson's disease (PD). We have identified a protein, termed PPM1H, that counteracts...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Establishing the Therapeutic Potential of Engineered Neural Circuits in a Preclinical Model of Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is caused by the death of specific brain cells that connect two different regions of the brain, disrupting a neural circuit that is key for motor function. We...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Investigating the Neuroprotective Potential and Mechanism of Action of an Inhibitor of the Rho-associated Protein Kinase (ROCK)
Study Rationale: Altered signaling through the Rho-associated protein kinase (ROCK) pathway has been found to play a role in the cellular pathogenesis of Parkinson’s disease (PD). Previously, we...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Modulation of Glycine for the Treatment of Parkinson’s Disease
Study Rationale: Levodopa, currently the best treatment for the symptoms of Parkinson’s disease (PD), eventually leads to the development of uncontrollable involuntary movements, called dyskinesia. In...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Development of Small-molecule Inhibitors that Reduce the Aggregation of Tau for the Treatment of Parkinson’s Disease
Study Rationale: The aggregation of alpha-synuclein and tau converts these proteins from a biologically functional state into toxic, fibrous deposits in the brains of people with Parkinson’s disease...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Development of an Inhibitor of Tau Aggregation to Treat Parkinson’s Disease
Study Rationale: The formation of tau aggregates is caused by excessive modification and abnormal folding of the tau protein in the brain, which leads to cellular dysfunction and neurodegeneration...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.